From the American Academy of Ophthalmology

This randomized, double-masked study showed that in patients with previously untreated wet AMD, a 2.0 mg dose was not superior to the 0.5 mg dose, and did not offer any incremental improvement in efficacy outcomes. Still, both doses resulted in significant improvements in BCVA, with an increase of 10.1 letters for the 0.5 mg monthly group and 9.2 letters for the 2.0 mg monthly group. The ranibizumab 0.5-mg and 2.0-mg PRN groups did not meet a prespecified noninferiority comparison. However, all treatment groups experienced clinically meaningful visual improvement. PRN groups required about 4 fewer injections than the monthly groups. Ophthalmology, May 2013